MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Gastroenterology
Gastroenterology

Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study

MedXY Editorial TeamJan 12, 2026
Gastric CancerHER2immunotherapyZanidatamab

Highlights

Unprecedented Survival Data

The combination of zanidatamab, tislelizumab, and CAPOX chemotherapy achieved a median overall survival (mOS) of 32.4 months, a significant milestone in the first-line treatment of HER2-positive advanced gastric cancer.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Optimizing Treatment Strategies for Gastric Cancer with Positive Peritoneal Cytology or Localized Peritoneal Metastasis

GastroenterologyOct 22, 2026

Long-term Outcomes of Neoadjuvant Nivolumab and Ipilimumab in MSI-High Gastric and GEJ Adenocarcinoma: Insights from the Phase 2 NEONIPIGA Trial

GastroenterologyOct 21, 2026

A Novel Endoscopic Classification Predicts Fundoplication Integrity and Pathologic Reflux After Antireflux Surgery

GastroenterologyNov 5, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story